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Abstract 
Ovarian cancer is highly metastatic with a poor prognosis. The serine/threonine kinase, 
p70 S6 kinase (p70S6K), which is a downstream effector of phosphatidylinositol 
3-kinase/Akt pathway, is frequently activated in ovarian cancer. Here, we show that 
p70S6K is a critical regulator of the actin cytoskeleton in the acquisition of the metastatic 
phenotype. This regulation is through two important activities: p70S6K acts as an actin 
filament cross-linking protein and as a Rho family GTPase-activating protein. Ectopic 
expression of constitutively active p70S6K in ovarian cancer cells induced a marked 
reorganization of the actin cytoskeleton and promoted directional cell migration. Using 
cosedimentation and differential sedimentation assays, p70S6K was found to directly bind 
to and cross-link actin filaments. Immunofluorescence studies showed p70S6K colocalized 
with cytochalasin D-sensitive actin at the leading edge of motile cells. p70S6K did not 
affect the kinetics of spontaneous actin polymerization, but could stabilize actin filaments 
by the inhibition of cofilin-induced actin depolymerization. In addition, we showed that 
p70S6K stimulated the rapid activation of both Rac1 and Cdc42, and their downstream 
effector p21-activated kinase (PAK1), but not RhoA. Depletion of p70S6K expression or 
inhibition of its activity resulted in significant inhibition of actin cytoskeleton 
reorganization and reduced migration, with a concomitant reduction in Rac1, Cdc42, and 
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PAK1 activation, confirming that the effect was p70S6K specific. Similarly, the actin 
cytoskeleton reorganization/migratory phenotype could be reversed by expression of 
dominant negative Rac1 and Cdc42, or inhibition of PAK1. These results reveal a new 
direction for understanding the oncogenic roles of p70S6K in tumor progression. 
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Introduction 
Ovarian cancer is the leading cause of death among all gynecological malignancies 
(Jemal et al., 2009). Nearly 70% of patients are diagnosed at the advanced stages, which 
have already metastasized cancer cells that detach from the primary tumor, spread 
throughout the peritoneum forming malignant ascites, adhere to and eventually invade 
organs within the peritoneal cavity. No effective therapy for advanced or metastatic 
ovarian carcinoma is currently available, and the poor 5-year survival rate is <25%. Thus, 
it is important to better understand the mechanisms by which these cells acquire 
metastatic properties and to identify new potential molecular targets.  
 
p70 S6 kinase (p70S6K) is a downstream effector of the phosphatidylinositol 3-kinase 
(PI3K)/Akt pathway, which is frequently activated in human ovarian cancer (Shayesteh et 
al., 1999; Philp et al., 2001; Altomare et al., 2004). p70S6K is also well known to be 
activated by cytokines and growth factors, including epidermal growth factor and 
hepatocyte growth factor (HGF), which are potent inducers of p70S6K in ovarian cancer 
(Liu et al., 2006; Zhou and Wong, 2006). Constitutive activation of p70S6K is significantly 
more prevalent in malignant ovarian tumors than in benign lesions (Castellvi et al., 2006). 
Recently, in addition to its well-established role in regulating proliferation and cell 
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survival, we show for the first time that p70S6K may be involved in other aspects of 
ovarian cancer progression, such as metastasis (Wong et al., 2004; Zhou and Wong, 2006; 
Pon et al., 2008). However, the role of p70S6K in cell migration, which is a key process 
directly linked to cancer invasion and metastasis, has not been established, and the 
mechanism by which p70S6K contributes to this process is also unknown. 
 
Reorganization of the actin cytoskeleton is both essential and central for cell migration 
(Pantaloni et al., 2001). Motile cancer cells must assemble and disassemble the actin 
filaments at their leading edges as they move forward. Thus, deregulation of the 
expression or properties of actin-binding proteins that regulate the 
polymerization/depolymerization of actin into filaments, and cross-linking of these into 
bundles could influence metastasis (Pawlak and Helfman, 2001). The Rho family of small 
GTPases, in particular Rac1, Cdc42, and RhoA, are molecular switches that control the 
organization and dynamics of the actin cytoskeleton (Ridley et al., 2003; Raftopoulou and 
Hall, 2004): Rac1 regulates the formation of membrane ruffles (lamellipodia), Cdc42 
triggers membrane projections (filopodia), and RhoA regulates stress fiber and focal 
adhesions. In addition, Rac1 is essential for forward cellular movement and Cdc42 is 
required for dictating the direction of migration.  
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In the present study, we show for the first time a role for p70S6K in the directed migration 
of human ovarian cancer cells. We also provide mechanistic insights suggesting that this 
tumorigenic activity is associated with the ability of p70S6K to directly and indirectly 
reorganize the actin cytoskeleton through its actin filament cross-linking and 
Rac1/Cdc42-activating activities.  
 
Results 
p70S6K activation causes reorganization of the actin cytoskeleton 
The rapid reorganization of the actin cytoskeleton is a critical early event in cell 
migration (Pantaloni et al., 2001). To address if p70S6K modifies actin organization in the 
cell, we tested the effects of constitutively active p70S6K activation on the actin 
cytoskeleton in CaOV-3 and SKOV-3 ovarian cancer cell lines, which represent advanced 
human ovarian cancer (Buick et al., 1985). When constitutively active p70S6K (ΔN54ΔC104 
and D3E-E398) was ectopically expressed, there was a marked difference in both cellular 
morphology and actin cytoskeleton architecture. ΔN54ΔC104- and D3E-E398-transfected 
cells had prominent actin-rich projections in the form of lamellipodia, actin microspikes, 
and filopodia which were absent in the untransfected cells (Figure 1a). Even after 24 h, 
there were no protrusions present in the control cells (data not shown).  
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To further demonstrate the effect of p70S6K in altering the actin cytoskeleton, we 
utilized a siRNA specifically engineered towards p70S6K. In these studies, HGF was used 
to activate endogenous p70S6K, because HGF is highly expressed in ovarian cancer ascites 
inducing migration of cultured ovarian cancer cells (Sowter et al., 1999). Overexpression 
of the HGF receptor Met is associated with ovarian cancer progression and high Met 
expression correlates with poor survival (Sawada et al., 2007). The p70S6K-specific 
siRNA, but not the nonspecific siRNA, was effective in depleting p70S6K expression as 
confirmed by Western blotting (Figure 1b, inset). We observed that p70S6K siRNA treated 
ovarian cancer cells resulted in dramatically reduced HGF-stimulated actin reorganization 
and reduced formation of membrane protrusions (Figure 1b). A second p70S6K specific 
siRNA was also used, and comparable results were obtained, which confirms that p70S6K 
was responsible for this effect (data not shown). In contrast, nonspecific siRNA did not 
obviously alter the pattern of actin distribution. Similar results were observed in cells 
treated with rapamycin, which is a small molecule inhibitor of p70S6K kinase activity 
(Figure 1b). Together, these data show that p70S6K activation plays a critical role in the 
reorganization of actin cytoskeleton. 
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p70S6K is required for directional migration 
Because directed cell migration is a prerequisite of metastasis, we assessed the role of 
p70S6K on cell migration using scrape wounding assays combined with Golgi tracking 
(Ridley et al., 2003). We found that p70S6K siRNA treated cells migrated less efficiently 
than the control nonspecific siRNA treated cells, and also exhibited significantly reduced 
directional persistence (98% inhibition of a polarized orientation of the Golgi apparatus) 
in the presence of HGF (Figure 2a). The role of p70S6K in directional cell migration was 
further evaluated by measuring the movement of the cells towards a chemotactic stimulus 
using Boyden chamber assays. Activation of p70S6K significantly promoted a motile 
phenotype, as detected by a 2.8-fold increase in cell motility compared with control cells 
(Figure 2b). In contrast, the HGF-enhanced migration was effectively suppressed by 
siRNA-mediated depletion of p70S6K to near basal levels (Figure 2b). Under these 
conditions, and consistent with previous observation (Corps et al., 1997), HGF did not 
cause significant alterations of cell proliferation (Supplementary Figure 1). We also found 
no effect of constitutively active p70S6K on cell proliferation (Supplementary Figure 1), 
indicating that the increase in cell migration was not because of a proliferative effect.  
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p70S6K binds directly to actin 
To begin to understand the mechanism of p70S6K involvement in signaling the actin 
cytoskeleton, we used a cosedimentation assay to investigate if p70S6K binds actin 
filament in vitro. As shown in Figure 3a, endogenous active p70S6K readily cosedimented 
with actin. Moreover, stimulation of HGF increased the amount of phospho-p70S6K 
sedimented in the actin pellet, suggesting that activated p70S6K can more capably 
associate with actin.  
We further asked whether the interaction of p70S6K with actin by direct interaction or 
is mediated by other actin-binding proteins. To test this, an in vitro actin binding assay 
was performed using highly purified active p70S6K. Figure 3b shows that the purified 
p70S6K could be readily coprecipitated with actin in a concentration-dependent manner. 
p70S6K alone did not pellet, indicating that the pelleting is due to binding to F-actin 
(Figure 3c). The fact that no other proteins were involved indicates a direct association 
between p70S6K and actin. 
This interaction was additionally verified by colocalization analysis using 
immunofluorescence microscopy. While phospho-p70S6K was located diffusely through 
the control cells, it was translocated to and, interestingly, concentrated in lamellipodia, 
actin microspikes, and filopodia where it was extensively colocalized with actin upon 
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stimulation with HGF (Figure 3d, left). We further confirmed our results using 
myc-tagged D3E-E398. We found that D3E-E398 was colocalized with actin at membrane 
protrusions of lamellipodia and filopodia (Figure 3d, right). These changes were inhibited 
by disruption of actin filaments by cytochalasin D treatment (Figure 3e), indicating that 
the binding of p70S6K to the cytoskeleton is mediated by actin. Similar experiments with 
SKOV-3 revealed p70S6K-actin interaction indistinguishable from those in CaOV-3 
(Supplementary Figures 2a and b). 
 
p70S6K cross-links and stabilizes F-actin 
To further establish the role that p70S6K plays in the actin cytoskeleton, we repeated the 
cosedimentation assay, this time using a low-speed (14,000 g) to pellet the bundled or 
cross-linked actin filaments, while the free actin filaments remain in the supernatant. 
HGF caused the majority of actin filaments to pellet with endogenous phospho-p70S6K 
during low speed centrifugation, suggesting that active p70S6K is cross-linking individual 
filaments into actin bundles (Figure 4a and Supplementary Figure 2c). This was also 
examined using purified proteins: F-actin was detected in the supernatant when p70S6K 
was absent, but in the pellet when p70S6K was present, with an increasing shift between 
free to bundled actin with increasing molar concentrations of p70S6K (Figure 4b). Light 
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scattering assay was used to monitor the kinetics of p70S6K-induced actin bundle 
formation. Light scattering increased rapidly and reached almost steady state within 5 
min, indicating that p70S6K quickly binds to actin filaments. Light scattering also 
increased with increasing concentrations of p70S6K, suggesting that more actin bundles 
were formed (Figure 4c). We also used electron microscopy to visualize the F-actin 
bundling. In the absence of p70S6K, actin filaments formed a uniform meshwork of fine 
filaments but did not show bundling. In contrast, robust multifilament bundles were 
clearly seen (Figure 4d). These closely apposed bundles were often slightly curved, 
suggesting flexible cross-linking.  
The possibility of a physical interaction between p70S6K and actin suggests that 
p70S6K may affect the kinetics of actin polymerization. p70S6K did not change the rate or 
the extent of polymerization, suggesting that unlike other common activities of these 
proteins, actin polymerization is not a generic property of p70S6K (Figure 5a). On the 
other hand, p70S6K significantly decreased the rate and extent of actin filament 
depolymerization (Figure 5b). Fluorescence from pyrene-labeled F-actin decreased 
rapidly after addition of cofilin. This decrease in fluorescence was largely reduced with 
F-actin pre-incubated with purified p70S6K, suggesting p70S6K prevented 
depolyermization of F-actin induced by cofilin. These results indicate that in addition to 
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cross-linking of F-actin, p70S6K also stabilizes filaments.  
 
p70S6K induces activation of Rac1 and Cdc42 
We next sought to determine the molecular mechanism by which p70S6K regulates actin 
organization. Three members of the Rho family GTPases, Rac1, Cdc42, and RhoA, are 
best known for their effects on the actin cytoskeleton (Hall, 1998). In fibroblasts, it has 
been shown that Rho GTPases have the potential to regulate p70S6K, suggesting that 
p70S6K may be a downstream effector (Berven et al., 2004; Chou and Blenis, 1996). 
However, transfection with dominant negative Rac (N17Rac1), Cdc42 (N17Cdc42), or 
Rho (N19RhoA) failed to block p70S6K phosphorylation (activation) upon HGF 
stimulation in CaOV-3 cells (Supplementary Figure 3a). Similarly, ectopic expression of 
constitutively active Rac (L61Rac1), Cdc42 (V12Cdc42), and Rho (V14RhoA) were 
unable to activate p70S6K (Supplementary Figure 3b).  
Because its roles in actin cytoskeleton reorganization similar to the activation of Rho 
GTPases, we investigated if p70S6K might act upstream of Rho GTPases. To explore this 
possibility, we tested the effects of p70S6K on Rac1, Cdc42, and RhoA activation using a 
pull-down assay that specifically recognizes the active GTP-bound form. As shown in 
Figure 6a, HGF rapidly increased activities of Rac1 and Cdc42 within 15-30 min, and 
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Rac1 and Cdc42 activation also coincided with the activation of p70S6K. In addition, 
expression of active p70S6K potently stimulated the activation of both Rac1 and Cdc42, 
whereas it did not have an effect on RhoA (Figure 6a), which is consistent with its 
enrichment in lamellipodia and filopodia (Fig. 1). To further elucidate the activation of 
Rac1 and Cdc42 was p70S6K specific, we used siRNA. In cells transfected with p70S6K 
siRNA, but not control siRNA, the ability of HGF to activate Rac1 and Cdc42 was 
abrogated (90% inhibition) (Figure 6b). Similarly, HGF-dependent activation of Rac1 and 
Cdc42 was also blocked in the presence of rapamycin (80% inhibition) (Figure 6c). 
Similar results were obtained with SKOV-3 cells (Supplementary Figures 2d and e). 
These results identify p70S6K as an upstream regulator of Rac1 and Cdc42. 
 
Rac1 and Cdc42 are mediators of p70S6K-regulated actin reorganization 
To investigate if p70S6K signals the actin cytoskeleton via Rac1 and Cdc42, we examined 
the actin cytoskeleton of cells cotransfected with myc-tagged dominant negative mutants 
of Rac1 and Cdc42 and GFP-tagged constitutively active p70S6K. Expression of N17Rac1 
or N17Cdc42 was shown to clearly inhibit the p70S6K-induced restructuring of the actin 
cytoskeleton (Figure 7a). Conversely, constitutively active Rac1 and Cdc42 enhanced cell 
spreading and caused reorganization of the actin cytoskeleton (lamellipodia/filopodia) to 
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levels similar to those observed in p70S6K-expressing cells (Figure 7b). To explore the 
relationship between p70S6K and Rac1/Cdc42, we investigated a possible interaction 
between these two proteins. Figure 7c demonstrates a colocalization of phospho-p70S6K 
with Rac1/Cdc42 in HGF-stimulated cells, but not in control cells.  
The p21-activated kinase (PAK1) is a well-characterized effector of both Rac1 and 
Cdc42 and is essential for regulating leading edge actin dynamics (Dummler et al., 2009). 
Our finding that the activities of both Rac1 and Cdc42 are important in p70S6K-mediated 
actin cytoskeleton reorganization prompted us to assess the role of PAK. We found that 
p70S6K was able to stimulate the phosphorylation of PAK1, and that stimulation was lost 
in HGF-treated cells transfected with the p70S6K siRNA (Figure 8a). Knocking down 
PAK1 impaired the pronounced lamellipodia/filopodia phenotype in response to 
transfection of constitutively active p70S6K (Figure 8b). These cells also displayed a loss 
of the motile phenotype (Figure 8c). Another PAK1 siRNA also showed comparable 
results (Figure 8), whereas a nonspecific siRNA had no effect. These data demonstrate an 
essential role of Rac1/Cdc42/PAK1 signaling in actin cytoskeleton reorganization and the 
regulation of ovarian cancer cell motility downstream of p70S6K. 
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Discussion 
In this study, we have successfully identified p70S6K as a novel regulator of the actin 
cytoskeleton and found that it is pivotal for the directed migration of ovarian cancer cells. 
We show that two important properties underlie this function of p70S6K, namely actin 
cross-linking and Rac1 and Cdc42 activation (Figure 9). Several aspects of this function 
are worth highlighting. We showed for the first time that p70S6K was able to bind to 
F-actin with no other proteins involved, indicating direct binding of p70S6K to F-actin. 
The finding that p70S6K F-actin structures were cytochalasin D sensitive emphasizes the 
possibility that in vitro interactions of p70S6K with F-actin may represent direct 
interactions of p70S6K with actin filaments in vivo. Moreover, the binding of p70S6K to 
F-actin was more potent in the presence of phosphorylation than in its absence, 
suggesting a dynamic regulation of p70S6K association with the cytoskeleton and 
reinforces the notion that actin reorganization and cell migration are finely tuned events. 
This also implies that the actin-binding domain in p70S6K may normally be hidden when 
this protein is in an inactive conformation. 
 
An intriguing aspect concerns the biological function of such an interaction. The finding 
that p70S6K both cross-links and stabilizes actin filaments suggests a role for p70S6K in 
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regulating actin dynamics. Several key actin-binding proteins such as α-actinin, fimbrin, 
and fascin also function to regulate actin bundling (Holmes et al., 1976; Hanein et al., 
1997). Because p70S6K has a well-established role in protein synthesis, this interaction 
may also have significance in synthesizing local proteins important for propagating the 
migratory response. For example, β-actin mRNA has been shown to localize to the 
leading lamella and its active translation there is important for cell migration (Kislauskis 
et al., 1994; Latham et al., 1994).  
 
The Rho family of GTPases are critical regulators of actin reorganization. Studies using 
fibroblasts have suggested that Rho GTPases and p70S6K may reside on a common 
signaling pathway, and indeed these studies indicate that Rho GTPases are upstream 
activators of p70S6K (Chou and Blenis, 1996; Berven et al., 2004). In contrast to the 
above data, we found that, in ovarian cancer cells, Rac1 and Cdc42 did not regulate 
p70S6K function. Rather, Rac1 and Cdc42 are downstream effectors of p70S6K. One 
possible explanation is that this action may be cell-type dependent. Clearly, epithelial 
cells and fibroblasts display distinct architecture of the actin cytoskeleton. Rac has been 
demonstrated to evoke different responses depending on the cell type (Takaishi et al., 
1997; Sander et al., 1998). Another possibility, and one that is supported by the findings 
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reported here, is that it may be related to the different functions of p70S6K. It is interesting 
to note that activation of p70S6K by Rac1 and Cdc42 appears to be independent of the 
ability of these Rho GTPases to regulate the cytoskeleton (Chou and Blenis, 1996). In 
contrast, we show that Rac and Cdc42 mediate signaling from p70S6K is related to 
cytoskeletal reorganization, which Rac/Cdc42 are known to function during this process 
(Hall, 1998).  
 
The increase in Rac1 and Cdc42 activities in response to p70S6K sheds new light on the 
biochemical mechanism of p70S6K function and identifies p70S6K as a novel, important 
regulator of Rho GTPases. How does p70S6K control the function of Rac1/Cdc42? 
Guanine nucleotide exchange factors (GEFs) are known to activate Rho GTPases by 
regulating the exchange of GDP for GTP. The Dbl homology-Pleckstrin homology 
(DH-PH) motif, present in many of proteins such as GEFs, is responsible for activation of 
Rac1 and Cdc42 (Erickson and Cerione, 2004). However, p70S6K does not contain a 
DH-PH domain or other motifs that may elicit GEF activity. Given the fact that TOR 
proteins regulate Rho GTPase activity via a GTP exchange factor, ROM2, in yeast 
(Schmidt et al., 1997), it is possible that an additional protein, such as GEF, may be 
necessary for p70S6K-mediated Rac1/Cdc42 activation. We also showed an essential role 
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for PAK1 in Rac1/Cdc42-mediated actin cytoskeleton reorganization downstream of 
p70S6K. This finding is intriguing because PAK1 has been observed as the predominant 
isoform that is frequently activated in ovarian tumors and appears to be associated with 
tumor aggressiveness (Schraml et al., 2003; Siu et al., 2009). Once activated, PAK1 may 
locally affect the actin organization via direct phosphorylation of key signaling targets. 
For example, PAK1 phosphorylates and inactivates the actin-depolymerizing protein 
cofilin leading to actin filament stabilization (Dummler et al., 2009). The observation that 
p70S6K can also physically cross-link and stabilize the filaments suggests that multiple 
mechanisms that control stable actin structures are likely to be regulated by p70S6K and 
gives support that this kinase is a critical regulator of the actin cytoskeleton.  
 
The ability of p70S6K to modulate dynamics of the actin cytoskeleton suggests that many 
oncogenic pathways could govern tumor invasion/metastasis by modulating p70S6K. 
p70S6K activation did not cause significant alteration to the actin cytoskeleton of normal 
OSE (Supplementary Figure 4), which suggests that the effect may be specific to ovarian 
cancer cells. It also complements our previous finding and other studies that showed a 
differential effect on OSE (Wong et al., 2004; Theriault et al., 2007) and the acquisition 
of a motile, fibroblast-like phenotype in OSE may be regulated independent of PI3K and 
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is a slow process (Ahmed et al., 2006). We and others have described the frequent 
activation of p70S6K in ovarian cancer cells than in normal OSE, suggesting a critical role 
for p70S6K in ovarian cancer development and progression (Wong et al., 2004; Castellvi et 
al., 2006; Pon et al., 2008). The observation that p70S6K was highly expressed and 
activated in high-grade, poorly differentiated ovarian carcinomas further suggests that 
p70S6K may be associated with tumor aggressiveness. Possible involvement of p70S6K in 
the regulation of cell migration is also particularly intriguing because the malignant 
phenotypes from patients with advanced breast cancer, colon cancer, and hepatocellular 
carcinoma are also correlated with increased activation of p70S6K (Filonenko et al., 2004; 
Sahin et al., 2004; Nozawa et al., 2007). We found that active p70S6K was able to bind 
and cross-link actin filaments and regulate actin organization in HepG2 liver cancer cells 
(Supplementary Figure 5), further suggesting that the cytoskeletal function of p70S6K we 
propose here may have broad implications for other tumor cell types as well. 
 
In summary, the present study reveals the novel identification of the localization and 
function of p70S6K in the actin cytoskeleton. The results show that p70S6K has pivotal 
roles in regulating metastatic progression, and opens new areas for further investigation. 
Such findings greatly advance our understanding of the role of p70S6K in oncogenesis and 
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highlight that usefulness of targeting p70S6K to impede metastasis in ovarian cancer. 
 21
Materials and methods 
Cells and cell culture 
Institutional approval for experimentation with human tissues was obtained prior to this 
study. OSE-529, OSE-545, and OSE-547 were obtained from ovaries at laparoscopy from 
women having surgery for non-malignant gynecologic diseases. The human ovarian 
carcinoma cell lines CaOV-3 and SKOV-3 were gifts from Dr. N. Auersperg (University 
of British Columbia, Vancouver, B. C., Canada). Cells were cultured in media 
199:MCDB105 supplemented with 10% fetal bovine serum (FBS) for OSE and 5% FBS 
for ovarian cancer cell lines. HepG2 human liver cancer cell line was maintained in DME 
containing 5% FBS. Cells were grown in humidified atmosphere of 5% CO2 at 37oC. 
 
DNA constructs and transfection 
N17Rac1 and L61Rac1 constructs were kindly provided by Dr. A. Hall (Memorial 
Sloan-Kettering Cancer Center, New York, NY) (Olson et al., 1995). N17Cdc42, 
V12Cdc42, N19RhoA, and V14RhoA were obtained from UMR cDNA Resource Center 
(Missouri, MO). The myc-tagged constitutively active p70S6K (ΔN54ΔC104 and D3E-E398) 
were gifts from Dr. G. Thomas (Genome Research Institute, University of Cincinnati, 
Cincinnati, OH) (Jefferies et al., 1997). GFP-tagged D3E-E398 was constructed by 
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subcloning into pEGFP vector (Clontech). To express cDNA constructs, cells were 
transiently transfected with 1 μg of plasmid DNA per well in 6-well plates using 
Lipofectamine 2000 reagent (Invitrogen). 
 
Small interfering RNA 
p70S6K-specific siRNA (#3, 5’-GACAAAAUCCUCAAAUGUA-3’; #4, 
5’-GCAGGAGUGUUUGACAUAG-3’) (Pon et al., 2008), PAK1-specific siRNA (#1, 
5’-CAUCAAAUAUCACUAAGUC-3’; #2, 5’-CAACAAAGAACAAUCACUA-3’), and 
a nonspecific duplex oligo (5’-GGCTACGTCCAGGAGCGCA-3’) as a negative control 
were purchased from Dharmacon (Lafayette, CO). Cells were transfected overnight with 
20 nM of siRNA using siLectFect (Bio-Rad) following the manufacturer’s instruction.  
 
Western blotting 
Equal amounts of cell lysates were resolved by SDS-PAGE. The samples were incubated 
overnight at 4oC with the following primary antibodies: anti-c-myc (clone 9E10) 
(1:1,500), anti-phospho-p70S6K (Thr389) (1:1,000), anti-p70S6K (1:1,000), 
anti-phospho-S6 (Ser235/236) (1:1,000), anti-S6 (1:1,000), anti-phospho-PAK1 
(Ser144)/PAK2 (Ser141) (1:1,000), anti-PAK1 (1:1,000), (Cell Signaling), anti-Rac1 
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(clone 23A8) (1:1,000), anti-Cdc42 (1:250), anti-RhoA (clone 55) (1:250) (Upstate), and 
anti-β-actin (1:1,500) (Sigma). Proteins were visualized by enhanced chemiluminescence 
(Amersham).  
 
Fluorescence microscopy 
To detect F-actin, cells were fixed in 4% paraformaldehyde in PBS. Cells were 
permeabilized with 0.1% Triton X-100, blocked with 5% BSA, and then incubated with 
Texas red-conjugated phalloidin (4 units/ml; Molecular Probes) for 1 h at room 
temperature. Images were observed by confocal microscopy using a Leica DMRB. In 
some cases, cells were treated with 1 μM cytochalasin D (Calbiochem) (known to disrupt 
actin filaments) for 30 min prior to fixation.  
 
Actin binding assay 
Binding of p70S6K to actin was tested in a cosedimentation assay according to the 
manufacturer’s instructions (Cytoskeleton). Briefly, cell lysates were first precleared by 
centrifugation at 800 g for 6 min and then incubated in the presence or absence of 
polymerized rabbit α-skeletal muscle actin at room temperature for 30 min. The reaction 
mixtures were centrifuged at 150,000 g for 90 min. BSA, which does not bind actin, and 
 24
α-actinin, an actin-binding protein, were used as negative and positive controls, 
respectively. The supernatant and pellet were separated and equal amounts were analyzed 
by Western blotting using anti-phospho-p70S6K antibody.  
To examine whether p70S6K directly interacts with actin, purified recombinant 
human active p70S6K (R&D Systems) was used. After 1 h incubation at room temperature, 
actin filaments and bound purified proteins were pelleted by centrifugation at 100,000 g 
for 1 h at 20oC. Equal amounts of the pellet and supernatant were analyzed by 
SDS-PAGE and Coomassie Blue staining.  
 
Actin cross-linking assay 
Precleared cell lysates or purified p70S6K (R&D Systems) was added to 4.5 μM freshly 
prepared F-actin for 1 h at room temperature, and was then centrifuged at 14,000 g for 1 
min to sediment bundled F-actin, the linear, unbundled F-actin remains in the supernatant. 
Equal amounts of the pellet and supernatant were analyzed by SDS-PAGE and the gel 
was stained with Coomassie Blue.  
 
Light scattering and electron microscopy 
Changes in light scattering of unlabeled actin was monitored by 90o light scattering at 
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405 nm (Perkin Elmer). The change of light scattering was recorded after addition of 
polymerization buffer to purified p70S6K and G-actin. Electron microscopy was 
performed on samples after actin polymerization was complete, as monitored by light 
scattering. Samples were fixed by 0.05% glutaraldehyde, spotted onto carbon-coated 
formvar grids, and negative stained with 2% uranyl acetate. Images were recorded on a 
CCD camera with a Philips EM208s transmission electron microscope (Eindhoven, The 
Netherlands).  
 
Actin polymerization assay 
Purified G-actin (2.5 μM, 10% pyrene-labeled) was incubated with purified p70S6K for 30 
min, and polymerization was initiated with 0.1 volume of 10x polymerization buffer. To 
measure cofilin-induced depolymerization, 1 μM polymerized filaments were incubated 
with purified p70S6K for 30 min, and actin depolymerization was induced by the addition 
of 1 μM recombinant purified human cofilin (Cytoskeleton). The change in fluorescence 
was monitored over time with excitation at 355 nm and emission at 405 nm using a Victor 
X4 plate reader (Perkin Elmer).   
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Cell polarity and migration analysis 
Cells were cultured to confluency and scraped using a pipette tip. Cells at the wound edge 
with Golgi (anti-GM130, Sigma) polarized to the front-facing 120o sector were scored as 
positive for polarization. Migration assay was performed using a 24-well Transwell 
inserts (8 μm pore size; Millipore). Cells (1.5 × 104 per well) were placed in the upper 
chamber, and 5% serum was placed in the lower chamber as a chemoattractant. The 
migratory phenotype was determined by counting the cells that had migrated to the lower 
side of the filter. Results were presented as the mean cell number of five fields ± SD of 
triplicate experiments. 
 
Rac1, Cdc42, and RhoA activity assay 
Pull-down assays were performed to isolate the active GTP-bound form using the 
Rac1/Cdc42 and RhoA activation assay kits (Upstate) following the manufacturer’s 
instructions. Briefly, 10 μg of agarose conjugated GST-PAK-1 PBD fusion protein were 
added to the lysate and rotated for 1 h at 4oC. The beads were washed three times, eluted 
with sample buffer and immunoblotted for either Rac1 or Cdc42. A similar assay, using 
the Rhoketin Rho binding domain (RBD) as a GST fusion protein, was used to measure 
RhoA activation. For negative and positive controls, cell extracts were incubated with 1 
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mM GDP and 100 µM GTPγS, respectively.  
 
Statistical analysis 
Data were expressed as mean ± SD. Experiments were performed three times. Statistical 
significance was evaluated with Student's t test. P < 0.05 was considered to be significant. 
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Figure Legends 
Figure 1  p70S6K activation induces reorganization of the actin cytoskeleton. (a) CaOV-3 
and SKOV-3 cells were transfected with constitutively active p70S6K (ΔN54ΔC104 or 
D3E-E389). Cells were fixed and visualized by phase microscopy, or stained for F-actin 
using Texas red-conjugated phalloidin and observed by confocal microscopy. Whole cell 
lysates were analyzed for the levels of phosphorylated (p-) and total forms of S6 by 
Western blot analysis. (b) Cells were transfected with nonspecific (NS) or p70S6K siRNA 
or pretreated with rapamycin (Rp; 20 nM). Cells were then stimulated with HGF (10 
ng/ml) for 1 h, fixed, and stained with Texas red-conjugated phalloidin. Expression of 
p70S6K was analyzed by Western blotting. β-actin was included as a loading control. 
Arrows indicate representative lamellipodia (↑) and filopodia (▲). Bar, 10 μm. 
Quantification of lamellipodia/filopodia is expressed as the mean number per 200 cells. 
Data are mean ± SD of three independent experiments. *, P < 0.05 compared with 
control or HGF and NS siRNA treated cells. 
 
Figure 2  Directed cell migration is impaired in p70S6K knockdown cells. (a) 
Nonspecific (NS) or p70S6K siRNA cells were plated for the scrape-wound assay. Six 
hours after wounding, cells were fixed and stained with a Golgi marker (anti-GM130, red) 
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and nucleus (DAPI, blue). Percentage of cells exhibiting reoriented Golgi into the 120o 
sector facing the wound was quantified. (b) Cells were seeded onto transwell inserts for 
cell migration assays. Quantification of migrated cells is expressed as the mean number 
per five fields. Experiments were repeated three times, and data are shown as mean ± SD. 
*, P < 0.05 compared with control or HGF and NS siRNA treated cells. 
 
Figure 3  p70S6K directly binds to actin. (a) CaOV-3 cell lysates were allowed to react 
with F-actin and then sedimented at 150,000 g (high speed). Equal amounts of pellets and 
supernatants were analyzed by SDS-PAGE and blotted with anti-phospho (p)-p70S6K. (b) 
F-actin was incubated with different concentrations of purified active p70S6K (0.05, 0.1, 
0.2 μM) followed by high-speed cosedimentation. Equivalent samples of pellets and 
supernatants were resolved by SDS-PAGE and proteins were visualized by Coomassie 
Blue staining. (c) p70S6K was mixed with F-actin buffer and centrifuged in either the 
presence (+) or absence (-) of F-actin. (d) Cells were treated with HGF (10 ng/ml) or 
transfected with constitutively active p70S6K (D3E-E389) or (e) pretreated with 
cytochalasin D (Cyto D; 1 μM) for 30 min and then stimulated with HGF. Cells were 
fixed and stained with anti-p-p70S6K (green), anti-myc (green), or phalloidin (red) and 
observed by confocal microscopy. Data shown represent three independent experiments 
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performed with similar results. Bar, 5 μm.  
 
Figure 4  p70S6K cross-links and stabilzes F-actin. (a) CaOV-3 cell lysates were allowed 
to react with F-actin and sedimented at 14,000 g. Under this condition, the linear, 
unbundled F-actin is in the supernatant, whereas bundled F-actin sediment. Both pellet 
and supernatant were separated on SDS-PAGE and analyzed by Western blotting with 
anti-p-p70S6K. (b) F-actin (4.5 μM) was incubated with increasing concentrations of 
p70S6K (0.05, 0.1 μM) and actin cross-linking assays were performed. (c) F-actin (2.5 μM) 
alone (○) or incubated with increasing concentrations of p70S6K (■ 0.05 μM; ▲ 0.1 μM) 
was monitored at 405 nm. (d) Negatively stained electron micrographs of F-actin in the 
absence or presence of 0.1 μM purified p70S6K. Bar, 0.2 μm.  
 
Figure 5  p70S6K inhibits cofilin-induced actin depolymerization. (a) G-actin (2.5 μM, 
10% pyrene-labeled) was polymerized with the addition of actin polymerization buffer in 
the presence or absence of p70S6K (0.1 μM). (b) Pyrene-labeled actin filament 
disassembly was induced by addition of 1 μM recombinant purified human cofilin with or 
without 0.1 μM purified p70S6K. 
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Figure 6  Specific activation of p70S6K on Rac1 and Cdc42, but not RhoA. (a) CaOV-3 
cells were stimulated with HGF (10 ng/ml) for the indicated times (in minutes) or 
transfected with constitutively active p70S6K (D3E-E389). (b) In some cases, cells were 
transfected with nonspecific (NS) or p70S6K siRNA or (c) treated with rapamycin (Rp) 
before HGF stimulation. Lysates were analyzed for GTPase activation using pull-down 
assays as described in Materials and methods. GTP-bound (active) Rac1, Cdc42, and 
RhoA were examined by Western blotting. Alternatively, lysates were resolved in 
SDS-PAGE and blotted with anti-phospho (p)-p70S6K, total p70S6K, and Rac1, Cdc42 and 
RhoA. GTPγS served as a positive control and GDP was a negative control. The blots 
represent three independent experiments performed with similar results. 
 
Figure 7  Rac1 and Cdc42 mediate p70S6K-induced actin reorganization. (a) CaOV-3 
cells were cotransfected with GFP-tagged constitutively active p70S6K (D3E-E389) and 
dominant negative Rac1 (N17Rac1) or Cdc42 (N17Cdc42) or (b) constitutively active 
Rac1 (L6Rac1) or Cdc42 (V12Cdc42). F-actin was visualized with Texas Red phalloidin. 
(c) Cells were treated with HGF (10 ng/ml), fixed, and stained with anti-p-p70S6K (green) 
or anti-Rac1/Cdc42 (red) Bar, 5 μm. Quantification of lamellipodia/filopodia is expressed 
as the mean number per 200 cells of three independent experiments. *, P < 0.05 
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compared with cells expressing D3E-E389 or control cells. 
 
Figure 8  PAK1 is required for p70S6K function. (a) CaOV-3 cells were transfected with 
constitutively active p70S6K (D3E-E389) (left), nonspecific (NS) siRNA, or p70S6K siRNA 
before HGF stimulation (10 ng/ml) (right). Lysates were analyzed by Western blot using 
anti-phospho-PAKs. (b) Cells were cotransfected with GFP-tagged D3E-E389 and NS 
siRNA or PAK1 siRNA. F-actin was visualized with Texas Red phalloidin. Bar, 5 μm. 
Quantification of lamellipodia/filopodia is expressed as the mean number per 200 cells. (c) 
Cells were cotransfected with D3E-E389 and dominant negative Rac1 (N17Rac1), Cdc42 
(N17Cdc42), NS siRNA, or PAK1 siRNA. Transfected cells were seeded onto transwell 
inserts for cell migration assays. Quantification of migrated cells is expressed as the mean 
number per five fields. Data are mean ± SD of three independent experiments. *, P < 
0.05 compared with cells expressing D3E-E389.  
 
Figure 9  A model proposed to illustrate p70S6K in actin cytoskeleton reorganization and 
migration. p70S6K directly and indirectly reorganizes the actin cytoskeleton through 
cross-linking and stabilizing filaments and Rac1- and Cdc42-activating activities, which 
eventually leading to polarized actin structure and directed cell migration. 
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Supplementary Figure Legends 
Figure 1  Effects of HGF and constitutive activation of p70S6K on cell proliferation. 
Control, HGF-treated (10 ng/ml), vector, or constitutively active p70S6K 
(D3E-E389)-transfected cells cultured for 24 h were collected for MTT assay. A 
tetrazolium dye (MTT) [3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide] 
was added to a final concentration of 1 mg/ml, and plates were incubated for 4 h. The 
conversion of MTT to formazan was monitored by the absorbance of each well at 570 nm 
with 630 as the reference wavelength. The absorbance of control cells was arbitrarily set 
as 1, and cell growth was expressed as the fold changes compared with the control. 
Experiments were repeated three times, and data are shown as mean ± SD.  
 
Figure 2  p70S6K binds actin and promotes Rac1 and Cdc42 activation in SKOV-3 cells. 
(a) Cells were transfected with myc-tagged constitutively active p70S6K (D3E-E389), 
stained with phalloidin (red) or anti-myc (green), and observed by confocal microscopy. 
Bar, 5 μm. Polymeric α-skeletal muscle actin was incubated with cell lysates for 30 min 
followed by (b) high-speed (150,000 g) or (c) low-speed (14,000 g) actin 
cosedimentation assays. Equal amounts of pellets and supernatants were detected by 
Western blotting with anti-phospho (p)-p70S6K. (d) Cells were transfected with 
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nonspecific (NS) or p70S6K siRNA or (c) treated with rapamycin before HGF stimulation 
(10 ng/ml) and subjected to the pull-down assays. GST-bound (active) Rac1, Cdc42 and 
RhoA were analyzed by Western blot. GTPγS served as a positive control and GDP was a 
negative control.  
 
Figure 3  Rho GTPases are not required for p70S6K activation. (a) CaOV-3 cells 
transfected with control or myc-tagged dominant negative Rac1 (N17Rac1), Cdc42 
(N17Cdc42), or RhoA (N19RhoA) were analyzed by Western blotting after stimulation 
with HGF (10 ng/ml) for 1 h. (b) Lysates from CaOV-3 cells expressing control or 
constitutively active Rac1 (L61Rac1), Cdc42 (V12Cdc42), or RhoA (V14RhoA) were 
subjected to Western blotting. Membranes were probed initially for phospho (p)-p70S6K, 
followed by stripping and reprobing with antibodies to p70S6K. β-actin was included as a 
loading control. Exogenously expressed myc-tagged Rac, Cdc42, and Rho proteins were 
detected using a myc antibody.  
 
Figure 4  Effect of p70S6K activation on the actin cytoskeleton of normal OSE. (a) OSE 
-529, OSE-545, and OSE-547 cells were transfected with myc-tagged constitutively 
active p70S6K (D3E-E389). Cells were fixed and visualized by phase microscopy, or (b) 
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stained for F-actin with Texas red-conjugated phalloidin (red) or D3E-E389 with anti-myc 
(green) and observed by confocal microscopy. Bar, 5 μm.  
 
Figure 5  p70S6K binds to and cross-links F-actin and regulates actin organization in 
HepG2 cells. (a) Cells were transfected with constitutively active p70S6K (D3E-E389), 
stained with phalloidin, and observed by confocal microscopy. Bar, 5 μm. Polymeric 
α-skeletal muscle actin was incubated with cell lysates for 30 min followed by (b) 
high-speed (150,000 g) or (c) low-speed (14,000 g) actin cosedimentation assays. Equal 
amounts of pellets and supernatants were detected by Western blotting with anti-phospho 
(p)-p70S6K. (d) Cells were cotransfected with D3E-E389 and dominant negative Rac1 
(N17Rac1) or Cdc42 (N17Cdc42). F-actin was visualized with Texas Red phalloidin. 
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